Vaccinex Reports Second Quarter 2022 Results and Provides
Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell...
Source: globenewswire.com
Stay updated with breaking news from Pepinemab Program Overview. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell...
15.08.2022 - Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Phase 2 SIGNAL-HD Study Published in Nature Medicine Patient enrollment continues in ...